There is ongoing research regarding the triple association—hypomethylating agent, venetoclax, and FLT3 inhibitor—with anticipated results regarding efficacy and toxicities in the unfit or ASCT-ineligible AML-FLT3-positive patient [14]. The gene discussed is FLT3; the disease is acute myeloid leukemia.